Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 12:12:998641.
doi: 10.3389/fonc.2022.998641. eCollection 2022.

Use of period analysis to timely assess 5-year relative survival for breast cancer patients from Taizhou, Eastern China

Runhua Li  1 , Yabing Zheng  2 , Jiajia Huang  3 , Huijun Lei  1 , Mingzhi Xu  4 , Liangyou Wang  5 , Luyao Zhang  6 , Yongran Cheng  7 , Xiyi Jiang  7 , Huijuan Tang  7 , Zheng Shi  1 , Gang Chen  1 , Huijuan Zhou  1 , Zhijun Dai  8 , Dalin Lu  3 , Tianhui Chen  1   9
Affiliations

Use of period analysis to timely assess 5-year relative survival for breast cancer patients from Taizhou, Eastern China

Runhua Li et al. Front Oncol. .

Abstract

Objectives: While timely assessment of long-term survival for patients with breast cancer is essential for evaluation on early detection and screening programs, those data are extremely scant in China. We aimed to derive most up-to-date survival estimates and to predict future survival using the cancer registry data from Taizhou city, Eastern China.

Methods: Patients diagnosed with breast cancer during 2004-2018 from four cancer registries with high-quality data from Taizhou, Eastern China were included. Period analysis was used to calculate 5-year relative survival (RS) for the overall population and according to the stratification factors sex, age at diagnosis and geographic region. We further predict the upcoming 5-year RS during 2019-2023, using continuous data from three 5-year periods (2004-2008, 2009-2013 and 2014-2018) and a model-based period approach.

Results: Overall 6159 patients diagnosed with breast cancer during 2004-2018 were enrolled. The 5-year RS for breast cancer in 2014-2018 reached 88.8%, while women were higher compared to men (90.5% versus 83.7%) and urban areas were higher compared to rural areas (91.9% versus 86.7%). Additionally, we found a clear gradient by age at diagnosis, ranging from 94.8% for age<45 years to 83.3% for age>74 years. Projected overall 5-year RS for the upcoming 2019-2023 could reach 91.5% (84.8% for men and 93.5% for women).

Conclusions: We provided, for first time in China, using period analysis, most up-to-date 5-year RS (88.8%) for patients with breast cancer from Taizhou, Eastern China. We also demonstrate the 5-year RS has improved greatly over last 15 years, which has important implications for timely evaluation of early detection and screening programs.

Keywords: 5-year relative survival; breast cancer; cancer registry; period analysis; timely evaluation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
5-year relative survival of breast cancer patients by gender during 2004-2008, 2009-2013, 2014-2018 and 2019-2023.
Figure 2
Figure 2
5-year relative survival of breast cancer patients by age at diagnosis during 2004-2008, 2009-2013, 2014-2018 and 2019-2023.
Figure 3
Figure 3
5-year relative survival of breast cancer patients by areas during 2004-2008, 2009-2013, 2014-2018 and 2019-2023.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Trayes KP, Cokenakes SEH. Breast cancer treatment. Am Fam Physician (2021) 104:171–8. - PubMed
    1. Shulman LN, Willett W, Sievers A, Knaul FM. Breast cancer in developing countries: opportunities for improved survival. J Oncol (2010) 2010:595167. doi: 10.1155/2010/595167 - DOI - PMC - PubMed
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71:209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Wang YQ, Li HZ, Gong WW, Chen YY, Zhu C, Wang L, et al. . Cancer incidence and mortality in zhejiang province, southeast China, 2016: a population-based study. Chin Med J (Engl) (2021) 134:1959–66. doi: 10.1097/CM9.0000000000001666 - DOI - PMC - PubMed
    1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) (2021) 134:783–91. doi: 10.1097/CM9.0000000000001474 - DOI - PMC - PubMed

LinkOut - more resources